Last reviewed · How we verify
Toripalimab plus concurrent chemo-radiotherapy
Toripalimab is a PD-1 inhibitor that works by blocking the PD-1 receptor on T cells, allowing them to attack cancer cells.
Toripalimab is a PD-1 inhibitor that works by blocking the PD-1 receptor on T cells, allowing them to attack cancer cells. Used for Metastatic nasopharyngeal carcinoma, recurrent or metastatic nasopharyngeal carcinoma, Locally advanced or metastatic esophageal squamous cell carcinoma.
At a glance
| Generic name | Toripalimab plus concurrent chemo-radiotherapy |
|---|---|
| Sponsor | Sun Yat-sen University |
| Drug class | PD-1 inhibitor |
| Target | PD-1 |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
By blocking the PD-1 receptor, toripalimab prevents cancer cells from evading the immune system. This allows the immune system to recognize and attack cancer cells more effectively. Toripalimab is typically used in combination with other treatments, such as chemotherapy and radiation therapy, to enhance its anti-tumor effects.
Approved indications
- Metastatic nasopharyngeal carcinoma, recurrent or metastatic nasopharyngeal carcinoma
- Locally advanced or metastatic esophageal squamous cell carcinoma
Common side effects
- Fatigue
- Nausea
- Diarrhea
- Vomiting
- Anemia
- Thrombocytopenia
- Neutropenia
- Leukopenia
Key clinical trials
- Toripalimab Combined With Different Platinum-Based Induction Chemotherapy Regimens for Locally Advanced Nasopharyngeal Carcinoma (PHASE2)
- Concurrent Chemoradiotherapy Combined With Toripalimab and Surufatinib in the Treatment of Limited-Stage Small Cell Lung Cancer (PHASE2)
- A Single-center Phase II Study to Investigate the Immune Maintenance Therapy Pattern in Patients With Locally Advanced Head and Neck Squamous Cell Carcinoma Who Have Achieved MPR After Neoadjuvant Immunotherapy Combined With Chemotherapy (PHASE2)
- Induction Chemotherapy and Toripalimab Followed by Chemoradiotherapy for Large-volume Local Advanced NSCLC (PHASE2)
- Window of Opportunity in Preserving Laryngeal Function Trial (PHASE2)
- Phase II Exploratory Study of Toripalimab Combined With SBRT in HER2-Negative Breast Cancer Patients With Insensitivity to Neoadjuvant Chemotherapy (PHASE2)
- Gemcitabine + Docetaxel + Toripalimab Induction in Epstein-Barr Virus (EBV) Associated Nasopharyngeal Carcinoma(NPC) (PHASE2)
- PDT For Induction Therapy For Head And Neck Cancer (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: